Morgan Stanley
MXCT icon

Morgan Stanley’s MaxCyte MXCT Stock Holding History

Morgan Stanley’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.59M Sell
3,688,131
-745,562
-17% -$696K ﹤0.01% 4578
2025
Q4 		$6.87M Sell
4,433,693
-2,262,186
-34% -$3.61M ﹤0.01% 3937
2025
Q3 		$10.6M Sell
6,695,879
-329,584
-5% -$573K ﹤0.01% 3492
2025
Q2 		$15.3M Buy
7,025,463
+24,664
+0.4% +$59.7K ﹤0.01% 3063
2025
Q1 		$19.1M Buy
7,000,799
+2,592,546
+59% +$10.2M ﹤0.01% 2738
2024
Q4 		$18.3M Sell
4,408,253
-408,879
-8% -$1.55M ﹤0.01% 2837
2024
Q3 		$18.7M Buy
4,817,132
+177,970
+4% +$750K ﹤0.01% 2864
2024
Q2 		$18.2M Buy
4,639,162
+1,120,046
+32% +$4.82M ﹤0.01% 2769
2024
Q1 		$14.7M Sell
3,519,116
-3,442,904
-49% -$16.2M ﹤0.01% 3003
2023
Q4 		$32.7M Buy
6,962,020
+5,636,850
+425% +$21.9M ﹤0.01% 2883
2023
Q3 		$4.13M Sell
1,325,170
-296,847
-18% -$1.19M ﹤0.01% 3890
2023
Q2 		$7.45M Sell
1,622,017
-58,852
-4% -$270K ﹤0.01% 3449
2023
Q1 		$8.32M Buy
1,680,869
+120,348
+8% +$593K ﹤0.01% 3315
2022
Q4 		$8.52M Buy
1,560,521
+71,280
+5% +$437K ﹤0.01% 3233
2022
Q3 		$9.68M Sell
1,489,241
-65,599
-4% -$366K ﹤0.01% 3020
2022
Q2 		$7.35M Buy
1,554,840
+252,863
+19% +$1.25M ﹤0.01% 3397
2022
Q1 		$9.1M Sell
1,301,977
-74,248
-5% -$507K ﹤0.01% 3010
2021
Q4 		$14M Buy
1,376,225
+82,026
+6% +$881K ﹤0.01% 2545
2021
Q3 		$15.8M Buy
+1,294,199
New +$19.5M ﹤0.01% 2344

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley's MXCT Position: Q1 2026 in Review

Morgan Stanley reduced its MaxCyte (MXCT) stake by 17% in Q1 2026, selling an estimated $696K and leaving 3,688,131 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #4578.

Morgan Stanley first reported a position in MXCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $32.7M in Q4 2023. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Morgan Stanley held 3,688,131 shares of MaxCyte worth $2.59M as of Q1 2026.
  • Morgan Stanley sold 745,562 MaxCyte shares in Q1 2026, an estimated $696K.
  • MaxCyte made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4578 holding.
  • Morgan Stanley first reported a position in MaxCyte in Q3 2021 and has held it in 19 quarters since.
  • Morgan Stanley's MaxCyte position peaked at $32.7M in Q4 2023.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.